ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’
Published . Updated .
Rather than deplete malfunctioning B cells as many other emerging autoimmune drugs do, Ai3Bio’s therapies are designed to eliminate a particular group of T helper cells.
Directly affected
- No company is named in this report.
Indirectly affected
- FBT First Trust NYSE Arca Biotech ETF
GA selected FBT as a RELATED security because its canonical security name directly matches this event's themes: biotechs. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- XBIX CORGI ETF TR I U S BIOTECH 2X
GA selected XBIX as a RELATED security because its canonical security name directly matches this event's themes: biotechs. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Rather than deplete malfunctioning B cells as many other emerging autoimmune drugs do, Ai3Bio’s therapies are designed to eliminate a particular group of T helper cells.
Source: BioPharma Dive
First Trust NYSE Arca Biotech ETF (FBT) since this story, compared with the market
Since the first closing price after “ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’,” First Trust NYSE Arca Biotech ETF (FBT) is -2.63%. The S&P 500 fund (SPY) is +0.56% over the same days, a -3.19% difference versus the market.
Who gains and who loses around First Trust NYSE Arca Biotech ETF (FBT)
Companies carried with this story
- FBT First Trust NYSE Arca Biotech ETF
First Trust NYSE Arca Biotech ETF (FBT) is linked, with no stored direction, medium confidence in the 29 Sep 2026 story “ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’.” Reason on file: GA selected FBT as a RELATED security because its canonical security name directly matches this event's themes: biotechs. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- XBIX Corgi Etf Tr I U S Biotech 2X
Corgi Etf Tr I U S Biotech 2X (XBIX) is linked, with no stored direction, medium confidence in the 29 Sep 2026 story “ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’.” Reason on file: GA selected XBIX as a RELATED security because its canonical security name directly matches this event's themes: biotechs. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
First Trust NYSE Arca Biotech ETF (FBT)
“ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’” (29 Sep 2026) reaches First Trust NYSE Arca Biotech ETF (FBT) through this story.
For First Trust NYSE Arca Biotech ETF (FBT), the reason on file says GA selected FBT as a RELATED security because its canonical security name directly matches this event's themes: biotechs. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Also listed, Corgi Etf Tr I U S Biotech 2X (XBIX): GA selected XBIX as a RELATED security because its canonical security name directly matches this event's themes: biotechs. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates in the story, and the First Trust NYSE Arca Biotech ETF (FBT) price range
FBT traded between 256.21 and 275.01 across 20 sessions. The latest close on file is 265.38. XBIX traded between 31.99 and 37.71 across 6 sessions. The latest close on file is 31.99.
How strong the case is around First Trust NYSE Arca Biotech ETF (FBT)
21 out of 100
“ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’” scores 21 out of 100. The score uses 1 sources, and 2 linked companies.